Status:
UNKNOWN
Anti-inflmmation Treatment in Mood Disorder and Deep Learning Prediction Model
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Conditions:
Mood Disorder
Eligibility:
All Genders
20-65 years
Phase:
PHASE4
Brief Summary
This three-year study will enroll 180 patients with mood disorders (90 patients with major depressive disorder and 90 patients with bipolar disorder) and high pro-inflammatory cytokine levels. They wi...
Detailed Description
Multiple lines of evidence support the pathogenic role of neuro-inflammation in mood disorders. Our team has published a series of papers showing the inflammatory cytokines are related to severity of ...
Eligibility Criteria
Inclusion
- Age between 20 to 65 years old.
- The baseline pro-inflammatory cytokines level: soluble IL6 receptor (sIL-6)\>35,000pg/ml, or CRP\>1,500ng/ml, or sTNF-R1\>1,000pg/ml.
- Maintain psychiatric medication for more than three months.
- Voluntary patients and controls with signed informed consent proved by institutional review board (IRB).
Exclusion
- Patients have used aspirin, statin previously .
- Patients have gastrointestinal disease, history of gastrointestinal bleeding, hematology coagulation disease, sever liver and renal disease.
- Patients with schizophrenia, organic brain diseases, mental retardation.
- Patients with symptoms of substance abuse/dependence (except nicotine dependence) within 3 months.
- Patients with autoimmune, acute infection and critical medical illnesses .
- Patients who cannot cooperate the study protocol.
Key Trial Info
Start Date :
August 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2023
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04685642
Start Date
August 24 2020
End Date
July 31 2023
Last Update
December 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Taiwan, 11217